Colin D. Mansfield

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Tyrosine kinase inhibitor, masitinib, limits neuronal damage, as measured by serum neurofilament light chain concentration in a model of neuroimmune-driven neurodegenerative disease.

Tyrosine kinase inhibitor, masitinib, limits neuronal damage, as measured by serum neurofilament light chain concentration in a model of neuroimmune-driven neurodegenerative disease.

Journal: PloS one

Published: June 24, 2024

Categorization of the amyotrophic lateral sclerosis population via the clinical determinant of post-onset ΔFS for study design and medical practice.

Categorization of the amyotrophic lateral sclerosis population via the clinical determinant of post-onset ΔFS for study design and medical practice.

Journal: Muscle & nerve

Published: November 21, 2023

Correction: Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial.

Correction: Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial.

Journal: Alzheimer's research & therapy

Published: April 22, 2023

Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial.

Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial.

Journal: Alzheimer's research & therapy

Published: August 01, 2022

Efficacy and Safety of Masitinib in Corticosteroid-Dependent Severe Asthma: A Randomized Placebo-Controlled Trial.

Efficacy and Safety of Masitinib in Corticosteroid-Dependent Severe Asthma: A Randomized Placebo-Controlled Trial.

Journal: Journal of asthma and allergy

Published: September 18, 2021

Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial.

Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: September 01, 2021

Long-term survival analysis of masitinib in amyotrophic lateral sclerosis.

Long-term survival analysis of masitinib in amyotrophic lateral sclerosis.

Journal: Therapeutic advances in neurological disorders

Published: February 25, 2021

Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial.

Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial.

Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration

Published: July 09, 2019

Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacology.

Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacology.

Journal: Nature communications

Published: February 01, 2017

ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?

ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?

Journal: Frontiers in aging neuroscience

Published: July 25, 2016

Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study.

Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study.

Journal: Lancet (London, England)

Published: March 14, 2016

Rapid and clinically significant response to masitinib in the treatment of mucosal primary esophageal melanoma with somatic KIT exon 11 mutation involving brain metastases: A case report.

Rapid and clinically significant response to masitinib in the treatment of mucosal primary esophageal melanoma with somatic KIT exon 11 mutation involving brain metastases: A case report.

Journal: Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia

Published: October 12, 2015

Showing 1-12 of 18

Last Updated: 09/26/2026